NO305055B1 - Farmas°ytisk t°rr blanding, farmas°ytisk doseringsenhet, fremgangsmÕte ved fremstilling derav og fremgangsmÕte ved fremstilling av tabletter - Google Patents
Farmas°ytisk t°rr blanding, farmas°ytisk doseringsenhet, fremgangsmÕte ved fremstilling derav og fremgangsmÕte ved fremstilling av tabletter Download PDFInfo
- Publication number
- NO305055B1 NO305055B1 NO920958A NO920958A NO305055B1 NO 305055 B1 NO305055 B1 NO 305055B1 NO 920958 A NO920958 A NO 920958A NO 920958 A NO920958 A NO 920958A NO 305055 B1 NO305055 B1 NO 305055B1
- Authority
- NO
- Norway
- Prior art keywords
- weight
- medical
- tablets
- steroid compound
- mixture
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 87
- 238000000034 method Methods 0.000 title claims abstract description 53
- 239000003814 drug Substances 0.000 title description 10
- 238000002360 preparation method Methods 0.000 title description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 44
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims abstract description 27
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 229960001375 lactose Drugs 0.000 claims description 49
- 239000008101 lactose Substances 0.000 claims description 49
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 44
- -1 steroid compound Chemical class 0.000 claims description 35
- 150000001875 compounds Chemical class 0.000 claims description 17
- 238000007580 dry-mixing Methods 0.000 claims description 7
- 239000003826 tablet Substances 0.000 abstract description 62
- 239000003795 chemical substances by application Substances 0.000 abstract description 28
- 230000003637 steroidlike Effects 0.000 abstract description 11
- 230000003389 potentiating effect Effects 0.000 abstract description 10
- 239000002775 capsule Substances 0.000 abstract description 8
- 239000000843 powder Substances 0.000 abstract description 8
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 5
- 239000002552 dosage form Substances 0.000 abstract description 3
- 239000008187 granular material Substances 0.000 abstract description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 42
- 150000003431 steroids Chemical class 0.000 description 27
- 238000007907 direct compression Methods 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 238000005550 wet granulation Methods 0.000 description 10
- 229960004976 desogestrel Drugs 0.000 description 9
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 8
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 229960002568 ethinylestradiol Drugs 0.000 description 8
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 7
- 235000010980 cellulose Nutrition 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 238000005204 segregation Methods 0.000 description 6
- 238000007873 sieving Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 229960004400 levonorgestrel Drugs 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229960004977 anhydrous lactose Drugs 0.000 description 4
- 229960005156 digoxin Drugs 0.000 description 4
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 4
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 4
- 238000007908 dry granulation Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 4
- 229960001390 mestranol Drugs 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920003110 Primojel Polymers 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 3
- 229960000571 acetazolamide Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 229960001021 lactose monohydrate Drugs 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000583 progesterone congener Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- VUHJZBBCZGVNDZ-TTYLFXKOSA-N chlormadinone Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 VUHJZBBCZGVNDZ-TTYLFXKOSA-N 0.000 description 2
- 229960003996 chlormadinone Drugs 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 229940096516 dextrates Drugs 0.000 description 2
- 229960000648 digitoxin Drugs 0.000 description 2
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 238000009477 fluid bed granulation Methods 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000757 progestagenic effect Effects 0.000 description 2
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 229960002941 etonogestrel Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960005352 gestodene Drugs 0.000 description 1
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229940084921 micronized glyburide Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP91200524 | 1991-03-12 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO920958D0 NO920958D0 (no) | 1992-03-11 |
| NO920958L NO920958L (no) | 1992-09-14 |
| NO305055B1 true NO305055B1 (no) | 1999-03-29 |
Family
ID=8207548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO920958A NO305055B1 (no) | 1991-03-12 | 1992-03-11 | Farmas°ytisk t°rr blanding, farmas°ytisk doseringsenhet, fremgangsmÕte ved fremstilling derav og fremgangsmÕte ved fremstilling av tabletter |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5382434A (fr) |
| EP (1) | EP0503521B2 (fr) |
| JP (1) | JP3474210B2 (fr) |
| KR (1) | KR100198017B1 (fr) |
| CN (1) | CN1039086C (fr) |
| AT (1) | ATE125155T1 (fr) |
| AU (1) | AU651869B2 (fr) |
| CA (1) | CA2062428C (fr) |
| DE (1) | DE69203488T3 (fr) |
| DK (1) | DK0503521T4 (fr) |
| ES (1) | ES2077897T5 (fr) |
| FI (1) | FI100770B (fr) |
| GR (1) | GR3017737T3 (fr) |
| HK (1) | HK1002018A1 (fr) |
| IE (1) | IE67345B1 (fr) |
| NO (1) | NO305055B1 (fr) |
| NZ (1) | NZ241915A (fr) |
| ZA (1) | ZA921659B (fr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA924617B (en) | 1991-03-25 | 1994-05-27 | Boart International S A Pty Lt | A percussion drill bit |
| ZA939565B (en) * | 1993-12-21 | 1994-08-11 | Applied Analytical Ind Inc | Method for preparing low dose pharmaceutical products. |
| ZA939566B (en) * | 1993-12-21 | 1994-08-11 | Applied Analytical Ind Inc | Method for dry blend compression od medicaments. |
| US5976570A (en) * | 1993-12-21 | 1999-11-02 | Applied Analytical Industries, Inc. | Method for preparing low dose pharmaceutical products |
| US5928668A (en) * | 1993-12-21 | 1999-07-27 | Applied Analytical Industries, Inc. | Method for dry blend compression of medicaments |
| ZA949929B (en) * | 1993-12-23 | 1995-08-23 | Akzo Nobel Nv | Sugar-coated pharmaceutical dosage unit. |
| US6077533A (en) * | 1994-05-25 | 2000-06-20 | Purdue Pharma L.P. | Powder-layered oral dosage forms |
| BR9509019B1 (pt) * | 1994-09-22 | 2009-01-13 | comprimido isento de solventes orgÂnicos. | |
| IL115445A (en) * | 1994-10-17 | 1999-08-17 | Akzo Nobel Nv | Solid pharmaceutical compositions comprising low dosage active ingredient oil and excipient capable of binding water and their preparation |
| EP0820237A4 (fr) * | 1995-01-25 | 1999-01-20 | Wrigley W M Jun Co | Compose antiadherent ameliore et procedes de fabrication de la gomme a macher dans lequel il est utilise |
| DK0833642T3 (da) * | 1995-06-22 | 2002-06-10 | Akzo Nobel Nv | Komprimerede tør-granulerede desogestreltabletter |
| DE19652196A1 (de) | 1996-12-16 | 1998-06-18 | Jenapharm Gmbh | Homogene steroidhaltige Präformulierungen zur Herstellung niedrigdosierter fester und halbfester pharmazeutischer Zubereitungen |
| WO2000050041A1 (fr) * | 1999-02-24 | 2000-08-31 | Akzo Nobel N.V. | Compositions pharmaceutiques contenant une forme cristalline du progestagene (17alpha)-17-hydroxy-11-methylene-19-nor-pregna-4,15-diene-20-yn-3-one (org 30659) et du lactose |
| KR20010006835A (ko) * | 1999-03-25 | 2001-01-26 | 김선진 | 경구용 속붕해정 |
| DE19917347A1 (de) | 1999-04-16 | 2000-11-09 | Gsf Forschungszentrum Umwelt | Verfahren und Vorrichtung zum trockenen Anbringen von Substanzen an inhalierbare pulverförmige Trägerstoffe |
| ITMI991582A1 (it) * | 1999-07-16 | 2001-01-16 | Chiesi Farma Spa | Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala |
| FR2796840B1 (fr) * | 1999-07-26 | 2003-06-20 | Ethypharm Lab Prod Ethiques | Comprimes faiblement doses et procede de preparation |
| US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
| FR2801218B1 (fr) * | 1999-11-23 | 2001-12-28 | Hoechst Marion Roussel Inc | Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant |
| JP2003518038A (ja) * | 1999-12-20 | 2003-06-03 | ニコラス， ジェイ カークホフ， | 流動床噴霧乾燥によるナノ粒子製造方法 |
| US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
| JP5033297B2 (ja) * | 2000-07-20 | 2012-09-26 | カムピナ・ベスローテン・フェンノートシャップ | 結晶性の錠剤化用添加剤の製造方法、それにより得られる添加剤、およびその使用 |
| WO2002047693A2 (fr) * | 2000-12-14 | 2002-06-20 | Ortho-Mcneil Pharmaceutical, Inc. | Produits a base d'hormone steroide et leurs procedes de fabrication |
| JPWO2002069934A1 (ja) * | 2001-03-06 | 2004-07-02 | 協和醗酵工業株式会社 | 口腔内速崩壊性製剤 |
| CA2440365A1 (fr) * | 2001-03-06 | 2002-09-12 | Kyowa Hakko Kogyo Co., Ltd. | Utilisation d'une poudre sechee par atomisation contenant un alcool de sucre |
| PL366453A1 (en) * | 2001-05-01 | 2005-02-07 | Pfizer Products Inc. | Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency |
| US7118765B2 (en) | 2001-12-17 | 2006-10-10 | Spi Pharma, Inc. | Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms |
| US6962908B2 (en) | 2001-12-21 | 2005-11-08 | Warner Chilcott Company Inc. | Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
| JP4898431B2 (ja) | 2003-04-29 | 2012-03-14 | ザ ジェネラル ホスピタル コーポレイション | 複数薬物の持続放出のための方法およびデバイス |
| US7444197B2 (en) | 2004-05-06 | 2008-10-28 | Smp Logic Systems Llc | Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes |
| US7799273B2 (en) | 2004-05-06 | 2010-09-21 | Smp Logic Systems Llc | Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes |
| TWI356036B (en) * | 2004-06-09 | 2012-01-11 | Smithkline Beecham Corp | Apparatus and method for pharmaceutical production |
| US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
| EP2178540A4 (fr) * | 2007-08-01 | 2012-01-04 | Stellan Hjerten | Composition pharmaceutique destinée à être adsorbée sur la surface cellulaire de microbes pathogènes |
| AU2009303272A1 (en) * | 2008-10-10 | 2010-04-15 | Teva Women's Health, Inc. | Methods for treating vasomotor symptoms in castrated prostatic cancer patients with low dose cyproterone acetate |
| KR101817361B1 (ko) | 2009-03-09 | 2018-01-11 | 에스피아이 파르마, 인크. | 고도 압착성 및 내구성 직접 압축성 부형제 및 부형제 시스템 |
| HUP0900698A2 (en) | 2009-11-06 | 2011-06-28 | Richter Gedeon Nyrt | Pharmaceutical compositions of enhanced stability containing drospirenone and ethynyl estradiol and process for their preparation |
| EP2354150A1 (fr) * | 2010-02-09 | 2011-08-10 | Laboratoire Theramex | Procédé de préparation de gestodène |
| WO2012120365A1 (fr) | 2011-03-07 | 2012-09-13 | Aurobindo Pharma Limited | Composition pharmaceutique stable comprenant de l'éthinyl estradiol |
| CN102416003A (zh) * | 2011-12-08 | 2012-04-18 | 南京优科生物医药有限公司 | 一种制备恩替卡韦片剂的方法 |
| CN105307639B (zh) * | 2013-03-04 | 2020-06-30 | 博赏医药卢森堡责任有限公司 | 包含与载体颗粒结合的活性剂纳米颗粒的干药物组合物 |
| CZ309820B6 (cs) * | 2021-04-23 | 2023-11-08 | Pro.Med.Cs Praha A.S. | Způsob přípravy pevné lékové formy obsahující kompozici s nízkým obsahem účinné látky |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3626063A (en) * | 1959-08-11 | 1971-12-07 | Upjohn Co | Therapeutic compositions comprising 6-fluoro-16-methyl prednisolone, the 21 acylates and salts thereof |
| US3344030A (en) * | 1964-06-15 | 1967-09-26 | American Home Prod | Reinforced directly compressed nongranulated pharmaceutical crystalline lactose tables |
| US3423507A (en) * | 1966-02-25 | 1969-01-21 | Schering Corp | Method of treating benign prostratic hypertrophy |
| US3568828A (en) * | 1967-03-01 | 1971-03-09 | Squibb & Sons Inc | Modified sequential oral contraceptive |
| US3671633A (en) * | 1971-05-10 | 1972-06-20 | American Cyanamid Co | Process for tabletting acetazolamide |
| US3802914A (en) * | 1972-04-10 | 1974-04-09 | Kraftco Corp | Method of treating lactose |
| SE378109B (fr) * | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| DE2365103C3 (de) * | 1973-12-21 | 1980-08-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | V erwendung von Hormonen zur Kontrazeption |
| DE2524902C2 (de) * | 1975-06-02 | 1984-10-25 | Schering AG, 1000 Berlin und 4709 Bergkamen | Vorrichtung zur Inhalation von Arzneimitteln |
| US4143136A (en) * | 1976-11-20 | 1979-03-06 | Akzona Incorporated | Method of contraception |
| DE2716323C2 (de) * | 1977-04-07 | 1986-03-13 | Schering AG, 1000 Berlin und 4709 Bergkamen | Vorrichtung zur Inhalation von Arzneimitteln |
| NL8001593A (nl) * | 1980-03-18 | 1981-10-16 | Akzo Nv | Meerfasisch combinatiepreparaat voor orale anticonceptie. |
| US4628051A (en) * | 1983-09-26 | 1986-12-09 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
| DE3505433A1 (de) * | 1985-02-16 | 1986-08-21 | Basf Ag, 6700 Ludwigshafen | Direkttablettierhilfsmittel |
| DE3506276C1 (de) * | 1985-02-22 | 1986-04-24 | Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring | Direkttablettiermittel |
| US4916163A (en) * | 1985-06-04 | 1990-04-10 | The Upjohn Company | Spray-dried lactose formulation of micronized glyburide |
-
1992
- 1992-02-27 IE IE920634A patent/IE67345B1/en not_active IP Right Cessation
- 1992-03-05 ZA ZA921659A patent/ZA921659B/xx unknown
- 1992-03-05 CA CA002062428A patent/CA2062428C/fr not_active Expired - Lifetime
- 1992-03-06 AU AU12119/92A patent/AU651869B2/en not_active Expired
- 1992-03-09 DK DK92103963T patent/DK0503521T4/da active
- 1992-03-09 EP EP92103963A patent/EP0503521B2/fr not_active Expired - Lifetime
- 1992-03-09 ES ES92103963T patent/ES2077897T5/es not_active Expired - Lifetime
- 1992-03-09 AT AT92103963T patent/ATE125155T1/de active
- 1992-03-09 DE DE69203488T patent/DE69203488T3/de not_active Expired - Lifetime
- 1992-03-09 FI FI921023A patent/FI100770B/fi not_active IP Right Cessation
- 1992-03-10 NZ NZ241915A patent/NZ241915A/en not_active IP Right Cessation
- 1992-03-11 CN CN92101566A patent/CN1039086C/zh not_active Expired - Lifetime
- 1992-03-11 KR KR1019920003956A patent/KR100198017B1/ko not_active IP Right Cessation
- 1992-03-11 NO NO920958A patent/NO305055B1/no not_active IP Right Cessation
- 1992-03-12 JP JP05393692A patent/JP3474210B2/ja not_active Expired - Lifetime
-
1994
- 1994-03-22 US US08/216,236 patent/US5382434A/en not_active Expired - Lifetime
-
1995
- 1995-10-16 GR GR950402836T patent/GR3017737T3/el unknown
-
1998
- 1998-02-11 HK HK98101029A patent/HK1002018A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1064810A (zh) | 1992-09-30 |
| DK0503521T4 (da) | 2005-12-05 |
| EP0503521B1 (fr) | 1995-07-19 |
| CA2062428C (fr) | 2002-07-30 |
| NZ241915A (en) | 1994-04-27 |
| CN1039086C (zh) | 1998-07-15 |
| ATE125155T1 (de) | 1995-08-15 |
| KR920017656A (ko) | 1992-10-21 |
| DE69203488D1 (de) | 1995-08-24 |
| DK0503521T3 (da) | 1995-11-27 |
| ZA921659B (en) | 1992-11-25 |
| US5382434A (en) | 1995-01-17 |
| IE920634A1 (en) | 1992-09-23 |
| FI100770B (fi) | 1998-02-27 |
| DE69203488T3 (de) | 2006-07-06 |
| IE67345B1 (en) | 1996-03-20 |
| FI921023A (fi) | 1992-09-13 |
| EP0503521A1 (fr) | 1992-09-16 |
| AU1211992A (en) | 1992-09-17 |
| JPH0578251A (ja) | 1993-03-30 |
| NO920958L (no) | 1992-09-14 |
| JP3474210B2 (ja) | 2003-12-08 |
| KR100198017B1 (ko) | 1999-06-15 |
| HK1002018A1 (en) | 1998-07-24 |
| AU651869B2 (en) | 1994-08-04 |
| DE69203488T2 (de) | 1996-01-11 |
| EP0503521B2 (fr) | 2005-11-09 |
| ES2077897T3 (es) | 1995-12-01 |
| FI921023A0 (fi) | 1992-03-09 |
| NO920958D0 (no) | 1992-03-11 |
| CA2062428A1 (fr) | 1992-09-13 |
| ES2077897T5 (es) | 2006-06-16 |
| GR3017737T3 (en) | 1996-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO305055B1 (no) | Farmas°ytisk t°rr blanding, farmas°ytisk doseringsenhet, fremgangsmÕte ved fremstilling derav og fremgangsmÕte ved fremstilling av tabletter | |
| US8022053B2 (en) | Oral solid dosage forms containing a low dose of estradiol | |
| EP2409690B1 (fr) | Stabilité améliorée de formulations de progestogène | |
| KR102539030B1 (ko) | 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 | |
| AU700645B2 (en) | Process of making dosage units by wet granulation | |
| JP3720385B2 (ja) | 医薬顆粒 | |
| US5976570A (en) | Method for preparing low dose pharmaceutical products | |
| KR20070085558A (ko) | 저 용량의 에스트라디올을 함유하는 경구 고형 제형 | |
| US5928668A (en) | Method for dry blend compression of medicaments | |
| US4115563A (en) | Pharmaceutical steroid formulation | |
| KR20070087141A (ko) | 경구용 고형 피임약 | |
| US20060205701A1 (en) | Solid peroral contraceptive preparations | |
| EP0735862B1 (fr) | Procede de compression d'un melange sec de medicaments | |
| US20070072836A1 (en) | Solid peroral contraceptive preparations | |
| KR100349230B1 (ko) | 약제용과립및그제조방법 | |
| KR102210982B1 (ko) | 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 | |
| CA2176460C (fr) | Procede de compression d'un melange sec de medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |